MEDI:GATE NEWS Daewoong Pharmaceutical’s partner, begins global phase 2 clinical trial for botulinum toxin migraine treatment
Daewoong Pharmaceutical, operating profit of 17 billion won last year… 62% decrease from the previous year
![[특징주] Medytox,’weak’ on news of temporary suspension of manufacturing and sales of’Innotox stock’](https://cdn.econovill.com/news/thumbnail/202012/511625_414347_2227_v150.jpg "[특징주] Medytox,’weak’ on news of temporary suspension of manufacturing and sales of’Innotox stock’")